WHO guidelines on human genome editing: why countries need to follow them
By Sheetal Soni,
The Conversation
| 08. 22. 2021
The World Health Organisation (WHO) recently called on countries to stop any research that might lead to the birth of genetically edited human beings. The call was made with the release of the recommendations on human genome editing.
Human genome editing has great potential. It can improve human health and medicine by making changes to DNA in cells to correct, introduce or delete almost any DNA sequence which may cause disease. Other potential benefits include new ways to diagnose, treat and prevent genetic disorders, novel ways to treat infertility, increasing knowledge of human biology and contributing towards vaccine development.
The potential of this technology came into the spotlight in 2018 when Chinese scientist He Jiankui announced that he had edited the genomes of twin girls. His announcement was met with consternation among many scientists because it highlighted a significant gap in regulation.
In response, the WHO established a committee made up of a global multi-disciplinary panel of 18 experts. The committee was asked to develop standards for human genome editing.
After nearly three years the panel recently published...
Related Articles
By Jenny Lange, BioNews | 12.01.2025
A UK toddler with a rare genetic condition was the first person to receive a new gene therapy that appears to halt disease progression.
Oliver, now three years old, has Hunter syndrome, an inherited genetic disorder that leads to physical...
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
By Pam Belluck and Carl Zimmer, The New York Times | 11.19.2025
Gene-editing therapies offer great hope for treating rare diseases, but they face big hurdles: the tremendous time and resources involved in devising a treatment that might only apply to a small number of patients.
A study published on Wednesday...
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
